Tralokinumab for severe, uncontrolled asthma

Asthma is a long-term condition that affects the lungs and breathing. People with asthma have symptoms such as coughing, wheezing, chest tightness and breathlessness. Some people have symptoms despite trying various treatments or may suffer from more sudden ‘asthma attacks’. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening.
Tralokinumab is a new drug that could help people with severe asthma that remains uncontrolled despite other treatments. It is injected under the skin every two weeks. An advanced-stage clinical trial is currently exploring whether tralokinumab will be more effective in a particular subgroup of people with asthma, and could be targeted towards this patient population. If licensed, tralokinumab could provide a new treatment option for people with uncontrolled asthma, as it works differently compared to other currently available treatments.